Literature DB >> 12676884

Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans.

John Farrell1, Dean J Naisbitt, Nicola S Drummond, Jan P H Depta, F Javier Vilar, Munir Pirmohamed, B Kevin Park.   

Abstract

Sulfamethoxazole (SMX) is associated with hypersensitivity reactions. Identification of drug-specific lymphocytes from hypersensitive patients suggests involvement of the immune system. Lymphocytes from humans recognize SMX and nitroso-SMX (SMX-NO), whereas cells from sensitized rats recognize only SMX-NO. In this investigation, we study the nature of SMX-specific T cells in four species. Male rats, mice, and rabbits were immunized with SMX (50 mg kg-1) or SMX-NO (1 mg kg-1). Lymphocytes and/or splenocytes were isolated and incubated with SMX, SMX-hydroxylamine or SMX-NO and proliferation were measured. Lymphocytes were also isolated from SMX-hypersensitive patients (n = 3) and drug-specific proliferation was measured. In addition, rabbits were bled fortnightly for 4 months to determine whether SMX-NO-specific T cells cross-react with SMX. To confirm that SMX-NO responses were due to covalent binding and not cross-reactivity, cells were pulsed with SMX-NO and/or coincubated with glutathione. Splenocytes from mice, rats, and rabbits proliferated when stimulated with SMX-NO, but not SMX. A 2-h pulse with SMX-NO was sufficient for proliferation, whereas cells coincubated with SMX-NO and glutathione did not proliferate. Rabbit lymphocytes proliferated in the presence of SMX-NO and SMX-hydroxylamine, but not SMX. SMX-hydroxylamine was converted to SMX-NO in culture. The SMXNO-specific response of rabbit lymphocytes was maintained for at least 4 months and the cells did not cross-react with SMX. Human lymphocytes from hypersensitive patients proliferated in the presence of SMX and both metabolites. These results highlight important differences in T-cell recognition of drug (metabolite) antigens in animals that have been sensitized against a drug metabolite and patients with hypersensitivity to the drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676884     DOI: 10.1124/jpet.103.050112

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

2.  Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.

Authors:  Mahmoud Abouraya; James C Sacco; Brad S Kahl; Lauren A Trepanier
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

4.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

5.  Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.

Authors:  Sachin Bhusari; Mahmoud Abouraya; Marcia L Padilla; Marie E Pinkerton; Nicholas J Drescher; James C Sacco; Lauren A Trepanier
Journal:  Arch Toxicol       Date:  2010-03-11       Impact factor: 5.153

6.  Knowledge and attitudes of American pharmacists concerning sulfonamide allergy cross-reactivity.

Authors:  Geoffrey C Wall; Jane E Dewitt; Sally Haack; Anisa Fornoff; Darla K Eastman; Carrie F Koenigsfeld
Journal:  Pharm World Sci       Date:  2010-04-23

7.  Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Authors:  Yat Yee Wong; Eva G Rakasz; David J Gasper; Thomas C Friedrich; Lauren A Trepanier
Journal:  Toxicology       Date:  2016-08-23       Impact factor: 4.221

8.  A single-nucleotide polymorphism in the canine cytochrome b5 reductase (CYB5R3) gene is associated with sulfonamide hypersensitivity and is overrepresented in Doberman Pinschers.

Authors:  J M Reinhart; J Ekena; A C Cioffi; L A Trepanier
Journal:  J Vet Pharmacol Ther       Date:  2018-01-15       Impact factor: 1.786

Review 9.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

Authors:  James C Sacco; Mahmoud Abouraya; Alison Motsinger-Reif; Steven H Yale; Catherine A McCarty; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.